Compare AbbVie Inc (ABBV) vs NIO Inc. (NIO) Price & Performance

AbbVie (ABBV) trades at $252.61, down 0.84% on the day, with a bullish technical outlook supported by moving averages and strong support at $248. The company reported revenue of $61.16B in 2025, with EPS beats in recent quarters, though net income margin has trended down to 5.79%. Key growth drivers Skyrizi and Rinvoq are offsetting Humira declines, with positive clinical updates like the Phase 2 ELAHERE data at SGO 2026.

The stock offers a compelling buy case with a consensus price target of $266.33 (5.4% upside) and strong analyst support (68% buy ratings). However, risks include patent cliffs in the 2030s, high debt levels, and margin pressure. Dividend growth is recovering, supporting income investors, but execution on pipeline assets remains critical for sustained expansion.

NIO trades at $4.88, up 1.88% with bearish technical signals despite strong delivery growth. The company shows improving fundamentals with revenue reaching $87.49B in 2025 and narrowing losses, though negative profitability metrics persist. Recent June deliveries surged 62.9% year-over-year, supporting margin expansion expectations. Analyst sentiment remains mixed with 50% buy ratings amid ongoing cash burn concerns.

NIO presents a high-risk turnaround opportunity with accelerating delivery growth and improving margins, but substantial losses and negative cash flow require careful monitoring. The stock faces technical resistance near $5 while benefiting from EV sector momentum and premium positioning in China's competitive market.